Suppr超能文献

13-顺式维甲酸治疗所致骨骼骨质增生的演变

Evolution of skeletal hyperostoses caused by 13-cis-retinoic acid therapy.

作者信息

Pennes D R, Martel W, Ellis C N, Voorhees J J

机构信息

Department of Radiology, University of Michigan Medical Center, Ann Arbor 48109.

出版信息

AJR Am J Roentgenol. 1988 Nov;151(5):967-73. doi: 10.2214/ajr.151.5.967.

Abstract

Seven patients with disorders of keratinization (ichthyosis in six and Darier disease in one) were treated with 13-cis-retinoic acid and followed with annual skeletal surveys for 4-6 years. Six of the seven patients developed hyperostoses attributable to the retinoid therapy, manifested as multifocal entheseal calcifications or ossifications in both the axial and appendicular skeletons. In general, the earliest appearing hyperostoses became the largest with time, although in some instances, growth ceased at some foci and progressed at others. The severity of skeletal involvement was seemingly independent of dose, and may have been related to the patient's age at time of therapy. Involvement of the spine was earlier and more pronounced than the appendicular involvement, consisting of tiny hyperostoses arising from the corners of the vertebral bodies, primarily in the cervical and thoracic spine; these later matured into either discrete ossific spurs, or focal or flowing ossification of the anterior longitudinal ligament. The most prominent appendicular hyperostoses were at the tendinous or aponeurotic insertions on the calcaneus, were often unilateral or asymmetric when small, and became bilateral with time. Appendicular hyperostoses occurring at locations besides the calcanei were much smaller, often unilateral, and occurred later (generally between the third and fifth years of therapy). Our findings indicate that the earliest hyperostoses occurring in patients with 13-cis-retinoic acid occur in the spine and feet, and become the most prominent with time. Most appendicular hyperostoses occur later, are smaller, and frequently are asymmetric or unilateral.

摘要

7例角化异常患者(6例鱼鳞病,1例 Darier病)接受了13 - 顺式维甲酸治疗,并进行了为期4 - 6年的年度骨骼检查。7例患者中有6例出现了与维甲酸治疗相关的骨质增生,表现为轴骨和附属骨骼多灶性起止点钙化或骨化。一般来说,最早出现的骨质增生随着时间推移会变得最大,不过在某些情况下,一些病灶的生长会停止,而另一些则会继续发展。骨骼受累的严重程度似乎与剂量无关,可能与治疗时患者的年龄有关。脊柱受累比附属骨骼更早且更明显,表现为椎体角出现微小的骨质增生,主要在颈椎和胸椎;这些增生后来会成熟为离散的骨化骨刺,或前纵韧带的局灶性或连续性骨化。附属骨骼最明显的骨质增生位于跟骨的肌腱或腱膜附着处,小的时候通常是单侧或不对称的,随着时间推移会变为双侧。在跟骨以外部位出现的附属骨骼骨质增生要小得多,通常是单侧的,且出现较晚(一般在治疗的第三至五年之间)。我们的研究结果表明,13 - 顺式维甲酸治疗患者最早出现的骨质增生发生在脊柱和足部,随着时间推移会变得最为突出。大多数附属骨骼骨质增生出现较晚,较小,且常常不对称或为单侧。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验